胃肠道肿瘤表观遗传启动子改变与免疫编辑及免疫检查点抑制剂耐药
本研究通过新型生物信息学算法(proActiv)从短读RNA测序中量化可变启动子负荷(APB),将胃癌样本分为APB高、中、低三组,并结合单细胞RNA测序和人源化小鼠模型探究肿瘤免疫微环境。结果显示APB高胃癌T细胞杀伤活性降低、免疫耗竭特征明显,且对免疫检查点抑制耐药,APB高者无进展生存期显著更差(中位55天 vs 121天,HR 0.40,95%CI 0.18-0.93,p=0.032)。
要点
- APB高胃癌T细胞杀伤活性降低且呈免疫耗竭特征。
- APB高肿瘤对人源化小鼠几乎无T细胞浸润。
- APB高胃肠道肿瘤对免疫检查点抑制耐药。
核心结论
- 可变启动子使用与肿瘤微环境相关,导致免疫逃逸和免疫治疗耐药。
研究设计与样本
- 利用新型生物信息学算法(proActiv)从短读RNA测序推断启动子活性并量化APB,将样本分为APB高、中、低三组。
- 采用单细胞RNA测序分析瘤内免疫微环境,并使用人源化小鼠癌症体内模型探究肿瘤动力学、可变启动子使用与人类免疫系统的动态时间相互作用。
- 评估多个接受免疫治疗的胃肠道肿瘤队列中APB与治疗结局的相关性。
主要发现
- APB高胃癌肿瘤T细胞杀伤活性表达降低,并表现出免疫耗竭特征。
- 单细胞RNA测序分析证实APB高肿瘤中免疫群体分布不同且T细胞比例较低。
- 人源化小鼠体内研究显示APB与肿瘤生长存在明显时间关系,APB高肿瘤几乎无人类T细胞浸润。
- 免疫治疗胃肠道肿瘤患者分析证实APB高肿瘤对免疫检查点抑制耐药。
- APB高胃癌无进展生存期显著差于APB低者(中位55天 vs 121天,HR 0.40,95%CI 0.18-0.93,p=0.032)。
关键数值与推荐
- APB高胃癌 vs APB低胃癌:中位无进展生存期55天 vs 121天,HR 0.40,95%CI 0.18-0.93,p=0.032。
临床怎么用
- APB可作为胃肠道肿瘤免疫检查点抑制疗效的潜在预测标志物,APB高提示耐药和预后差。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Epigenomic alterations in cancer interact with the immune microenvironment to dictate tumour evolution and therapeutic response. We aimed to study the regulation of the tumour immune microenvironment through epigenetic alternate promoter use in gastric cancer and to expand our findings to other gastrointestinal tumours. DESIGN: Alternate promoter burden (APB) was quantified using a novel bioinformatic algorithm (proActiv) to infer promoter activity from short-read RNA sequencing and samples categorised into APBhigh, APBint and APBlow. Single-cell RNA sequencing was performed to analyse the intratumour immune microenvironment. A humanised mouse cancer in vivo model was used to explore dynamic temporal interactions between tumour kinetics, alternate promoter usage and the human immune system. Multiple cohorts of gastrointestinal tumours treated with immunotherapy were assessed for correlation between APB and treatment outcomes. RESULTS: APBhigh gastric cancer tumours expressed decreased levels of T-cell cytolytic activity and exhibited signatures of immune depletion. Single-cell RNAsequencing analysis confirmed distinct immunological populations and lower T-cell proportions in APBhigh tumours. Functional in vivo studies using 'humanised mice' harbouring an active human immune system revealed distinct temporal relationships between APB and tumour growth, with APBhigh tumours having almost no human T-cell infiltration. Analysis of immunotherapy-treated patients with GI cancer confirmed resistance of APBhigh tumours to immune checkpoint inhibition. APBhigh gastric cancer exhibited significantly poorer progression-free survival compared with APBlow (median 55 days vs 121 days, HR 0.40, 95% CI 0.18 to 0.93, p=0.032). CONCLUSION: These findings demonstrate an association between alternate promoter use and the tumour microenvironment, leading to immune evasion and immunotherapy resistance.
引用
- Sundar R, Huang KK, Kumar V, et al. Epigenetic promoter alterations in GI tumour immune-editing and resistance to immune checkpoint inhibition. Gut. 2021. PMID: 34433583. doi:10.1136/gutjnl-2021-324420
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。